ArticleTurk gogus kalp damar cerrahisi dergisi2025
Survival analysis between single-factor and multi-factor groups in Stage T3N0M0 non-small cell lung cancer.
Article in Turk gogus kalp damar cerrahisi dergisi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to identify prognostic factors in operated patients with non-small cell lung cancer staged as T3N0M0 according to the 8 Methods: Between January 2010 and June 2023, a total of 79 patients (67 males, 12 females; mean age: 62.9±8.7; range, 40 to 80 years) who underwent surgery for non-small cell lung cancer and were pathologically staged as T3N0M0 were retrospectively analyzed. The patients were divided into two groups: the first group included 56 patients with a single T3 factor, while the second group included 23 patients with multiple T3 factors. Survival analysis was performed. Results: The five-year overall survival rate for the first group was 79.0%, with a mean overall survival of 107.76±8.44 months (95% confidence interval [CI]: 91.21-124.32), while the second group had a five-year overall survival rate of 48.9%, with a mean overall survival of 69.19±12.60 months (95% CI: 44.48-93.91). This difference was statistically significant (p=0.02). In the multivariate analysis, multiple T3 factors (p=0.003) and the presence of comorbidity (p=0.004) were found to be independent poor prognostic factors. Conclusion: Our study results suggest that having multiple T factors significantly and adversely affect survival of patients with surgically treated pT3 non-small cell lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.